Abstract

 The systematic search resulted in 1 single-arm prospective study and 1 retrospective cohort study. No relevant randomized controlled trials, systematic reviews, or evidence-based guidelines were identified that met the criteria for this review.
 Evidence was limited, inconsistent, and of low quality for the clinical effectiveness of octreotide long-acting release in combination with everolimus in patients with recurrent meningiomas.
 The quantity and quality of current publications were not sufficient to draw a conclusion in support of or against the clinical effectiveness of octreotide long-acting release in combination with everolimus relative to other systematic therapies in patients with recurrent meningiomas.
 Additional research is required to inform decision-making in this context.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
